<DOC>
	<DOCNO>NCT00133107</DOCNO>
	<brief_summary>This study determine whether efalizumab 1.0mg/kg give subcutaneous injection 12 week effective treat oral lichen planus . This 20 week , single center , open-label pilot study enroll 5 subject .</brief_summary>
	<brief_title>Safety Effectiveness Efalizumab Treat Oral Lichen Planus</brief_title>
	<detailed_description />
	<mesh_term>Lichen Planus , Oral</mesh_term>
	<mesh_term>Lichen Planus</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Able provide write informed consent Subject able willing comply study requirement full duration study . Age &gt; 18 year . Subject diagnosis oral lichen planus deem investigator sufficient severity require systemic agent . The diagnosis make biopsy proven oral lichen planus biopsy proven cutaneous lichen planus set subject oral disease consistent lichen planus . Subject clinical lesion score least 2 . If female childbearing potential , subject negative urine pregnancy test screen week 0 . If female , subject either postmenopausal &gt; 1 year ; surgically sterile ( hysterectomy bilateral tubal ligation ) ; practice one form birth control ( abstinence , oral contraceptive , estrogen patch , implant contraception , injectable contraception , intrauterine device [ IUD ] , diaphragm , condom , sponge , spermicide , vasectomy partner ) . Female subject continue use contraception 3 month follow last injection . Subjects must stable dos topical medication , corticosteroid , cyclosporine , tacrolimus past 4 week . Patients know hypersensitivity Raptiva ( efalizumab ) component . Pregnant lactate woman Subject evidence clinically significant , unstable poorly control medical condition . Subject chest Xray consistent active infection previous exposure tuberculosis ( TB ) and/or positive purify protein derivative test screening ( &gt; 5 mm ) . ( Subjects may participate actively treat accordance Centers Disease Control [ CDC ] guideline . ) Subject serious , active recurrent bacterial , viral , fungal infection . This include hepatitis B C , HIV . Subject hospitalize infection receive intravenous ( IV ) antibiotic within previous 2 month prior baseline . Subject history tuberculosis without documented adequate therapy . Subject diagnose malignancy within past 5 year except successfully treat nonmelanoma skin cancer . Subject dermatologic disease target site may exacerbate treatment interfere examination . Subject administered investigational drug another clinical study within 30 day prior baseline ( 5 halflives , whichever long ) . Subjects observational study without investigational drug device may still enrol . Subject use follow systemic agent within 4 week prior week 0 : photochemotherapy , systemic corticosteroid , cyclosporine , tacrolimus , azathioprine , methotrexate , mycophenolate mofetil , hydroxychloroquine , chloroquine , quinacrine , dapsone , thalidomide . Subject previously treat biologic immune response modifier include alefacept , etanercept , infliximab , adalimumab within 12 week prior day 0 ( 5 halflives , whichever long ) . Subject previously treat efalizumab . Subject weigh 125 kg .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>